Latest research on Reyataz

Atazanavir (formerly known as BMS-232632) is an antiretroviral drug of the protease inhibitor (PI) class. Like other antiretrovirals, it is used to treat infection of human immunodeficiency virus (HIV). Atazanavir is distinguished from other PIs in that it can be given once-daily (rather than requiring multiple doses per day) and has lesser effects on the patient's lipid profile (the amounts of cholesterol and other fatty substances in the blood). Like other protease inhibitors, it is used only in combination with other HIV medications. The U.S. Food and Drug Administration (FDA) approved atazanavir on June 20, 2003. [Wikipedia]

Latest findings

Atazanavir (ATV) (or Reyataz) is generally used in combination with the boosting agent, Ritonavir (ATV/r), and is currently being developed as a fixed-dose combination with the boosting agent cobicistat (ATV/cobi). [source, 2015]
Atazanavir (brand name: Reyataz) developed by Bristol-Myers Squibb Co. (Princeton, NJ, USA) and approved in 2003, is an aza-dipeptide analog, which exhibits potent anti-HIV activity. [source, 2015]
In 1996 protease inhibitors were approved for treatment of patients with HIV and currently include saquinavir (Fortovase), Saquinavir Mesylate (Invirase), ritonavir (Norvir), amprenavir (Agenerase), lopinavir (Kaletra), Indinavir sulfate (Crixivan), nelfinavir mesylate (Viracept), and atazanavir sulfate (Reyataz). [source, 2014]
PubMed and EMBASE search terms were “HIV-1 [mesh] OR HIV infections [mesh] NOT pregnancy [mesh] AND ((dolutegravir OR GSK1349572) OR (Efavirenz OR Sustiva OR Stocrin OR DMP-266) OR (raltegravir OR Isentress OR MK-0518) OR (elvitegravir OR GS-9137 OR JTK-303) OR (rilpivirine OR Edurant OR TMC 278) OR (Darunavir OR Prezista OR TMC-114) OR (atazanavir OR Reyataz OR BMS-232632) OR (lopinavir OR ABT-378 OR Aluviran OR Koletra OR Kaletra) OR (Atripla OR Quad OR Stribild OR Eviplera OR Complera))”. [source, 2014]
Atazanavir (Reyataz, Bristol-Myers Squibb Pharma) and Ritonavir (Norvir, Abbot Laboratories Limited), Trimethoprim-sulfamethoxazole or Cotrimoxazole (Bactrim, Roche, France) and Metronidazole (Flagyl, Sanofi-aventis, France) and Bumetanide (Sigma, St. Quentin-Fallavier, France) were commercially available. [source, 2014]
ATV, an azapeptide, was developed originally by Ciba-Geigy and sold under the trade name Reyataz by Bristol-Myers Squibb. [source, 2014]
She was on highly active anti-retroviral therapy (HAART) including Norvir, Reyataz and Truvada for 10 years. [source, 2013]
Medication used in the clinical study was Reyataz 200 mg ATV sulphate capsules from Bristol-Myers Squibb, Bedfordview, Gauteng, South Africa, and Sutherlandia SU1 300 mg SF tablets from Phyto Nova, Cape Town, Western Cape, South Africa. [source, 2013]
On Day 1 of the study (start of Phase I), subjects received a light meal before a single 400 mg (2 × 200 mg capsules) dose of ATV (Reyataz, Bristol-Myers Squibb, Bedfordview, Gauteng, South Africa) was administered to each with a 240 mL glass of water. [source, 2013]
aDrugs with sales above $100 million in 2010: Atripla ($2927 million), Truvada ($2746 million), Reyataz ($1479 million), Kaletra ($1255 million), Isentress ($1090 million), Prezista ($888 million), Epzicom ($858 million), Combivir ($561 million), Norvir ($344 million), Sustiva ($315 million), Viramune ($295 million), Intelence ($243 million), Trizivir ($223 million), Crixivan ($206 million), Epivir ($178 million), Ziagen ($159 million), Selzentry ($124 million), Viracept ($112 million); values from EvaluatePharma [23]. [source, 2013]